These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2524206)

  • 1. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.
    Madden S; Back DJ; Martin CA; Orme ML
    Br J Clin Pharmacol; 1989 Mar; 27(3):295-9. PubMed ID: 2524206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.
    Back DJ; Houlgrave R; Tjia JF; Ward S; Orme ML
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):219-25. PubMed ID: 2004043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro.
    Wild MJ; Rudland PS; Back DJ
    J Steroid Biochem Mol Biol; 1993 May; 45(5):407-20. PubMed ID: 8499348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal metabolism of contraceptive steroids.
    Back DJ; Madden S; Orme ML
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2138-45. PubMed ID: 2147818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of the contraceptive steroid desogestrel by human liver in vitro.
    Madden S; Back DJ; Orme ML
    J Steroid Biochem; 1990 Feb; 35(2):281-8. PubMed ID: 2137889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
    Orme M; Back DJ; Ward S; Green S
    Contraception; 1991 Apr; 43(4):305-16. PubMed ID: 1830266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings.
    Jung-Hoffmann C; Kuhl H
    Contraception; 1990 Oct; 42(4):423-38. PubMed ID: 2147887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings.
    Timmer CJ; Apter D; Voortman G
    Contraception; 1990 Dec; 42(6):629-42. PubMed ID: 2150632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel.
    Hasenack HG; Bosch AM; Käär K
    Contraception; 1986 Jun; 33(6):591-6. PubMed ID: 2945700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers.
    Rogers SM; Back DJ; Orme ML
    Br J Clin Pharmacol; 1987 Jun; 23(6):727-34. PubMed ID: 3606932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
    Back DJ; Grimmer SF; Shenoy N; Orme ML
    Contraception; 1987 Jun; 35(6):619-26. PubMed ID: 2959449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol.
    Olsson SE; Odlind V
    Contraception; 1990 Nov; 42(5):563-72. PubMed ID: 2272184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human urinary and liver conjugates of 17alpha-ethnylestradiol.
    Helton ED; Williams MC; Goldzieher JW
    Steroids; 1976 Jun; 27(6):851-67. PubMed ID: 941195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of desogestrel.
    McClamrock HD; Adashi EY
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1021-8. PubMed ID: 8447355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel.
    Kuhl H; Jung-Hoffmann C; Heidt F
    Contraception; 1988 Sep; 38(3):381-90. PubMed ID: 2971509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of a combined contraceptive vaginal ring releasing ethinyloestradiol and 3-ketodesogestrel on vaginal flora.
    Davies GC; Feng LX; Newton JR; Dieben TO; Coelingh-Bennink HJ
    Contraception; 1992 May; 45(5):511-8. PubMed ID: 1623721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.